Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Deley, Marie-Cécile Le; Paulussen, Michael; Lewis, Ian; Brennan, Bernadette; Ranft, Andreas; Whelan, Jeremy; Teuff, Gwénaël Le; Michon, Jean; Ladenstein, Ruth; Marec‐Bérard, Perrine; Berg, Henk van den; Hjorth, Lars; Wheatley, Keith; Judson, Ian; Juergens, Heribert; Craft, Alan; Oberlin, Odile; Dirksen, Uta

doi:10.1200/jco.2013.54.4833

Cited by 152 publications

(145 citation statements)

References 27 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…VAC was statistically not inferior to VAI; however, 3-year EFS was slightly higher for patients receiving VAI. 39 Various dosage paradigms of VAC-IE (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) have been investigated. Although dose escalation of alkylating agents in VAC-IE did not improve outcomes for patients with localized disease, 40 chemotherapy intensification through interval compression has been shown to improve outcomes.…”

Section: Chemotherapymentioning

confidence: 99%

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Biermann

Chow

Reed

et al. 2017

J Natl Compr Canc Netw

225

187

View full text Add to dashboard Cite

show abstract

Section: Chemotherapymentioning

confidence: 99%

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Biermann

Chow

Reed

et al. 2017

J Natl Compr Canc Netw

225

187

View full text Add to dashboard Cite

show abstract

“…[4][5][6] Multimodal therapy includes systemic therapy as well as surgery and radiotherapy (RT). 7 Until now, clinical trials on ES have principally focused on a comprehensive investigation of systemic treatment.…”

mentioning

confidence: 99%

Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background. Primary Ewing sarcoma (ES) can sometimes present as a chest-wall tumor. Multidisciplinary management, including chemotherapy and local treatment consisting of surgery, radiotherapy (RT), or both, has improved the survival of patients with localized ES; however, the best approach to achieving local control remains controversial.Methods. We retrospectively analyzed data from 198 patients with non-metastatic ES of the chest wall, who were registered in the database of the German Society of Pediatric Hematology and Oncology between July 1998 and April 2009. The majority of patients (n = 130) presented with rib tumors; 7 patients received RT only, 85 patients underwent surgery alone, and 106 patients were treated with a combination of surgery and RT. Results. Overall survival in all patients was 78 and 71 % at 3 and 5 years, respectively. Event-free survival at 5 years (5-year EFS) was 57 % in the RT group, 73 % in the surgery group and 63 % in the surgery ? RT group. In patients with complete resections, 5-year EFS did not improve with the addition of RT compared with surgery alone. There was no difference in the 5-year EFS in patients with partial (63 %) or total (64 %) resection of the affected ribs, and median follow-up was 4.71 years (range 0.40-13.48). Conclusions. Complete tumor resection is the best way to achieve local control of ES of the chest wall; additional RT is only useful in patients with incomplete resection. The main limitation of this study was its retrospective nature, and the benefit of total resection of the affected ribs could not be proved.Ewing sarcoma (ES) is a rare, highly malignant disease found in children, adolescents, and young adults, with a reported incidence of three persons per million people per year within a Caucasian population. Median age at diagnosis is 15 years, 1 and the chest wall is the primary site of presentation in 14 % of patients. The tumor most commonly originates from osseous structures (ribs 9 %, scapula 4 %, clavicle 1 %, or sternum \1 %), and even less frequently from the soft tissue of the chest wall (\1 %). 2 ESs of the chest wall have also been referred to as Askin's tumors, 3 until an identical molecular signature revealed a common origin.Multidisciplinary management has improved the 5-year survival of patients with localized disease to rates of 60-70 % and higher. 4-6 Multimodal therapy includes systemic therapy as well as surgery and radiotherapy (RT). 7 Until now, clinical trials on ES have principally focused on a comprehensive investigation of systemic treatment. 8-10 Although multi-agent chemotherapy is well defined as the standard of care for ES patients, the best approach for local control of ES of the chest wall remains a matter of discussion. 11 Local treatment of chest-wall tumors is often challenging, especially in young patients, as both local treatment modalities (surgery and RT) may be associated with significant long-term sequelae. 12 Due to the rarity of ES of the chest wall, only a limited number of patient series have been publis...

show abstract

“…Recent clinical studies which combined these modalities have shown survival rates of near 80% 8,9 although results from our country were slightly inferior 10 . Local control of the tumor in patient with ES is tried to be ensure with surgery and/or radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Üriner İnkontinansın Alışılmadık Bir Nedeni: Ewing Sarkomu

Küpeli¹

2015

Cukurova Medical Journal

View full text Add to dashboard Cite

Urinary incontinence in children can be originated mostly from urinary tract infections, but constipation, neurologic disorders, obstruction and tumors can also be considered among other causes. Pelvic tumors may present with back pain, bladder or bowel dysfunction. Ewing's sarcoma is among the small round-cell tumors of the childhood and potentially can arise from any part of the body. Here, we report an 11-year-old male presented with urinary incontinence and diagnosed as Ewing's sarcoma after 6 weeks' delay. Clinicians should suspect from pelvic tumors in the presence of urinary incontinence especially associated with low back pain.

show abstract

Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

Cited by 152 publications

References 27 publications

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial

Üriner İnkontinansın Alışılmadık Bir Nedeni: Ewing Sarkomu

Contact Info

Product

Resources

About